Quick Takeaways
- Paragon Therapeutics, Inc. filed SCHEDULE 13G for Galecto, Inc. Common Stock, par value $0.00001 per share (GLTO).
- Disclosed ownership: 7.5%.
- Date of event: 10 Nov 2025.
Paragon Therapeutics, Inc. - 10 Nov 2025 SCHEDULE 13G Report for Galecto, Inc. Common Stock, par value $0.00001 per share (GLTO)
- Filing Manager
- Paragon Therapeutics, Inc.
- Reporting Manager
- Paragon Therapeutics, Inc.
- Symbol
- GLTO
- Shares outstanding
- 1,606,307 shares
- Disclosed Ownership
- 120,473 shares
- Ownership
- 7.5%
- Form type
- SCHEDULE 13G
- Filing time
- 12 Jan 2026, 16:01:02 UTC
- Date of event
- 10 Nov 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Paragon Therapeutics, Inc. disclosed 7.5% ownership in Galecto, Inc. Common Stock, par value $0.00001 per share (GLTO) on 10 Nov 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 12 Jan 2026, 16:01.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Paragon Therapeutics, Inc. | 7.5% | 120,473 | 120,473 | 0 | /s/ Keri Lantz | Keri Lantz, Chief Financial Officer |